Literature DB >> 18078867

The relationship between plasma asymmetrical dimethyl-L-arginine and inflammation and adhesion molecule levels in subjects with normal, impaired, and diabetic glucose tolerance.

Dildar Konukoglu1, Sinem Firtina, Ozden Serin.   

Abstract

Increasing evidence suggests that the postprandial state is a contributing factor to the development of atherosclerosis. To evaluate the effects of acute hyperglycemia on endothelial dysfunction and inflammation, plasma asymmetrical dimethyl-l-arginine (ADMA), intercellular adhesion molecule 1 (sICAM-1), vascular cell adhesion molecule 1, and C-reactive protein (CRP) levels and secretory phospholipase A(2) (sPLA(2)) activities were measured in subjects with normal (n = 35), impaired (IGT) (n = 25), and diabetic (DGT) (n = 20) glucose tolerance. At baseline, plasma ADMA, sICAM-1, and CRP concentrations and plasma sPLA(2) activities were higher in both the IGT and DGT groups than in the normal glucose tolerance group (for each comparison, each P < .001). Patients with DGT have higher plasma ADMA and sICAM-1 concentrations than patients with IGT (for each, P < .001).Two hours after glucose loading, plasma ADMA and CRP concentrations and sPLA(2) activities were significantly elevated in the 3 groups when compared with baseline levels (for each comparison, P < .001). Plasma vascular cell adhesion molecule 1 and sICAM-1 concentrations were found to be elevated from baseline levels after glucose loading in the IGT and DGT groups (for each comparison, P < .001). Correlation analysis at baseline suggested that there was a significant relationship between ADMA and inflammation and soluble adhesion markers in the studied groups. In conclusion, plasma concentrations of ADMA and of inflammation and adhesion molecules were elevated in the prediabetic state. A complex interrelation could exist between ADMA and inflammation, and mechanisms involved in endothelial dysfunction are multifactorial at the prediabetic and diabetic state.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18078867     DOI: 10.1016/j.metabol.2007.08.013

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  7 in total

1.  Decreasing high postprandial stearic acid in impaired fasting glucose by dietary regulation.

Authors:  L Liu; X Chu; L Na; F Yuan; Y Li; C Sun
Journal:  Eur J Clin Nutr       Date:  2016-01-06       Impact factor: 4.016

2.  ADMA (asymmetric dimethylarginine) and angiogenic potential in patients with type 2 diabetes and prediabetes.

Authors:  Radosław Wieczór; Anna M Wieczór; Arleta Kulwas; Danuta Rość
Journal:  Exp Biol Med (Maywood)       Date:  2020-09-22

3.  Clinical evaluation of extracellular ADMA concentrations in human blood and adipose tissue.

Authors:  Marcus May; Sandor Batkai; Alexander A Zörner; Dimitrios Tsikas; Jens Jordan; Stefan Engeli
Journal:  Int J Mol Sci       Date:  2014-01-17       Impact factor: 5.923

Review 4.  Asymmetric dimethylarginine and all-cause mortality: a systematic review and meta-analysis.

Authors:  Shaoli Zhou; Qianqian Zhu; Xiang Li; Chaojin Chen; Jiping Liu; Yuping Ye; Ying Ruan; Ziqing Hei
Journal:  Sci Rep       Date:  2017-03-15       Impact factor: 4.379

Review 5.  Exploratory metabolomics of metabolic syndrome: A status report.

Authors:  Daniella Lent-Schochet; Matthew McLaughlin; Neeraj Ramakrishnan; Ishwarlal Jialal
Journal:  World J Diabetes       Date:  2019-01-15

6.  A Protein/Lipid Preload Attenuates Glucose-Induced Endothelial Dysfunction in Individuals with Abnormal Glucose Tolerance.

Authors:  Domenico Tricò; Lorenzo Nesti; Silvia Frascerra; Simona Baldi; Alessandro Mengozzi; Andrea Natali
Journal:  Nutrients       Date:  2020-07-10       Impact factor: 5.717

7.  Oxidative Stress and Arginine/Nitric Oxide Pathway in Red Blood Cells Derived from Patients with Prediabetes.

Authors:  Sonia Eligini; Benedetta Porro; José Pablo Werba; Nicolò Capra; Stefano Genovese; Arianna Greco; Viviana Cavalca; Cristina Banfi
Journal:  Biomedicines       Date:  2022-06-14
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.